Dana J. Lukin
A5047191452- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Autoimmune and Inflammatory Disorders
- Gut microbiota and health
- Diagnosis and treatment of tuberculosis
- Immunodeficiency and Autoimmune Disorders
- Helicobacter pylori-related gastroenterology studies
- Diverticular Disease and Complications
- Clostridium difficile and Clostridium perfringens research
- Pregnancy and Medication Impact
- IL-33, ST2, and ILC Pathways
- Spondyloarthritis Studies and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Biosimilars and Bioanalytical Methods
- Colorectal Cancer Screening and Detection
- Gastric Cancer Management and Outcomes
- Celiac Disease Research and Management
- Liver Diseases and Immunity
- Chronic Lymphocytic Leukemia Research
- Cancer-related Molecular Pathways
- Mycobacterium research and diagnosis
- COVID-19 Clinical Research Studies
- Autoimmune and Inflammatory Disorders Research
- Adolescent and Pediatric Healthcare
Cornell University
2019-2025
Weill Cornell Medicine
2020-2024
Presbyterian Hospital
2019-2024
New York Hospital Queens
2019-2024
NewYork–Presbyterian Hospital
2019-2024
Albert Einstein College of Medicine
2015-2021
Montefiore Medical Center
2015-2020
New York Proton Center
2020
Dana (United States)
2019
GTx (United States)
2019
Doublecortin-like kinase 1 protein (DCLK1) is a gastrointestinal tuft cell marker that has been proposed to identify quiescent and tumor growth-sustaining stem cells. DCLK1⁺ cells are increased in inflammation-induced carcinogenesis; however, the role of these within epithelium their potential as cancer-initiating poorly understood. Here, using BAC-CreERT-dependent genetic lineage-tracing strategy, we determined subpopulation extremely long lived possesses rare abilities. Moreover, ablation...
Objectives: We assessed the real-world effectiveness and safety of vedolizumab (VDZ) in moderate–severe Crohn’s disease (CD). Methods: Retrospective cohort study seven medical centers, from May 2014 to December 2015. Adults with moderate-severe CD treated VDZ, follow-up after initiation therapy, were included. Using multivariable Cox proportional hazard analyses, we identified independent predictors clinical remission or mucosal healing VDZ. Rates serious infection (requiring antibiotics,...
Glutathione (GSH) is a major source of reducing equivalents in mammalian cells. To examine the role GSH synthesis development and cell growth, we generated mice deficient by targeted disruption heavy subunit γ-glutamylcysteine synthetase (γGCS-HS tm1 ), an essential enzyme synthesis. Embryos homozygous for γGCS-HS fail to gastrulate, do not form mesoderm, develop distal apoptosis, die before day 8.5. Lethality results from apoptotic death rather than reduced proliferation. We also isolated...
We aimed to quantify the safety and effectiveness of vedolizumab (VDZ) when used for UC, identify predictors response treatment.Retrospective review (May 2014-December 2016) VICTORY Consortium data. Adults with follow-up after starting VDZ clinically active UC were included. Primary outcomes cumulative rates clinical remission (resolution all UC-related symptoms) endoscopic (Mayo sub-score 0). Key secondary included corticosteroid-free deep (clinical remission). Cox proportional hazard...
As more treatment options for inflammatory bowel diseases become available, it is important to identify patients most likely respond different therapies. We created and validated a scoring system with Crohn's disease (CD) who vedolizumab.
N ew York City is the epicenter of US coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome 2 (SARS-CoV-2) with local population infection rates estimated at 25%. 1 The impact COVID-19 on patients inflammatory bowel (IBD) within an not well understood.Our study aims were to compare clinical outcomes between and without IBD investigate prevalence risk factors in patients. MethodsA matched cohort design was used or IBD.The source all COVID-19-positive New...
We evaluated the real-world effectiveness and safety of ustekinumab (UST) in patients with Crohn's disease (CD).This study used a retrospective, multicenter, multinational consortium UST-treated CD patients. Data included patient demographics, phenotype, activity, treatment history, concomitant medications. Cumulative rates clinical, steroid-free, endoscopic, radiographic remissions were assessed using time-to-event analysis, clinical predictors by multivariate Cox proportional hazard...
Upadacitinib, an oral Janus kinase inhibitor, achieved significantly higher rates of clinical remission and endoscopic response vs placebo during induction (U-EXCEL [NCT03345849], U-EXCEED [NCT03345836]) maintenance (U-ENDURE [NCT03345823]) treatment in patients with moderate-to-severe Crohn's disease. Prior biologic failure is often associated reduced responses to subsequent therapies. This post hoc analysis assessed upadacitinib efficacy by prior status.
Innate lymphoid cells (ILCs) can promote host defense, chronic inflammation, or tissue protection and are regulated by cytokines neuropeptides. However, their regulation diet microbiota-derived signals remains unclear. We show that an inulin fiber promotes Tph1-expressing inflammatory ILC2s (ILC2INFLAM) in the colon, which produce IL-5 but not tissue-protective amphiregulin (AREG), resulting accumulation of eosinophils. This exacerbates inflammation a murine model intestinal damage ILC2-...
Abstract The tumor suppressor p53 (TP53) has a well-studied role in triggering cell-cycle checkpoint response to DNA damage. Previous studies have suggested that functional enhances chemosensitivity. In contrast, data are presented show can be required for cell survival following damage due activation of reversible checkpoints. cellular outcome is determined by the duration and extent stimulus p53-dependent manner. transient or low levels damage, triggers G2 arrest, whereas sustained arrest...
There are few real-world data on the safety of vedolizumab for treatment Crohn's disease (CD) or ulcerative colitis (UC). We quantified rates and identified factors significantly associated with infectious non-infectious adverse events in clinical practice.We performed a retrospective review from multicenter consortium database (from May 2014 through June 2017). Infectious were defined as those requiring antibiotics, hospitalization, discontinuation, resulting death. Rates proportions per...
Background & AimsWe created and validated a clinical decision support tool (CDST) to predict outcomes of vedolizumab therapy for ulcerative colitis (UC).MethodsWe performed logistic regression analyses data from the GEMINI 1 trial, 620 patients with UC who received induction maintenance (derivation cohort), identify factors associated corticosteroid-free remission (full Mayo score 2 or less, no subscore above 1). We used these develop model treatment, which we called CDST. evaluated...
Abstract Background We quantified loss of response (LOR) to vedolizumab (VDZ) in clinical practice and assessed the effectiveness VDZ dose intensification for managing LOR. Methods Retrospective review (May 2014–December 2016) a prospectively maintained inflammatory bowel disease (IBD) registry. Kaplan-Meier estimates were used determine rates LOR . Independent predictors identified using univariate multivariable Cox proportional hazard regression. Success recapturing (>50% reduction...
Summary Background Direct comparisons are lacking between vedolizumab and tumour necrosis factor (TNF)‐antagonist therapy in Crohn's disease (CD). Aim To compare safety effectiveness of TNF‐antagonist adult CD patients. Methods Retrospective observational cohort (May 2014–December 2017) propensity score‐weighted comparison vs (infliximab, adalimumab, certolizumab) CD. Propensity scores were weighted for age, prior treatments, complications, extent severity, steroid dependence, concomitant...
Background & AimsPatients with Crohn's disease (CD), but not ulcerative colitis (UC), of shorter duration have higher rates response to tumor necrosis factor (TNF) antagonists than patients longer duration. Little is known about the association between and other biologic agents. We aimed evaluate CD or UC vedolizumab, stratified by duration.MethodsWe analyzed data from a retrospective, multicenter, consortium (n = 650) 437) treated vedolizumab May 2014 through December 2016. Using time event...
Sulfasalazine is a prodrug known to be effective for the treatment of inflammatory bowel disease (IBD)-associated peripheral spondyloarthritis (pSpA), but mechanistic role gut microbiome in regulating its clinical efficacy not well understood. Here, 22 IBD-pSpA subjects with sulfasalazine identifies responders enriched Faecalibacterium prausnitzii and capacity butyrate production. Sulfapyridine promotes production transcription synthesis gene F. vitro, which suppressed by excess folate....